Summer Sale
50% off Premium Yearly
00days
00hrs
00mins
00secs
NYSE:PFE
Pfizer Inc (PFE)
26.17
+0.57 (2.23%)
as of Jun 11, 2026, 8:00:00 pm Market Open.
322 watching
Financials 
Technical Analysis 0
BUY
Got in on the Celebrex recall. This company has developed some fantastic drugs. Pharmaceutical stocks in the US have been absolutely decimated. Dirt cheap. 3.5% didvidend yield while you wait for a recovery. Generates a ton of free cash flow. Merck & Company (MRK-N) are in the same way.
biotechnologypharmaceutical
PAST TOP PICK
WEAK BUY
Pharmaceuticals have pretty good cash flows, but their stocks are going nowhere. Cheap on a relative basis to where they've been. Have one big overhang as a group, i.e., there are a lot of patent expiries that are going to happen in 2006. May not be a bad time to start picking them up.
Martin Hubbes, CFAOwned
biotechnologypharmaceutical
BUY
TOP PICK
Likes the pharmaceutical industry. The market is not thinking about the tremendous amount of cash they throw off and that they are cheap. Made the right move by not taking Celebrex off the market. Good pipeline.
Paul Harris, CFAOwned
biotechnologypharmaceutical
BUY
BUY
FDA has given the OK on the controversial drugs. Pfizer is a very strong company and has the best pipeline of all the large drug companies. Continues to generate billions of $'s of free cash flow. YOu won't get rich, but you'll make some money.
Andrew McCreathOwned
biotechnologypharmaceutical
BUY
Likes this one a lot. Trading at 11 X earnings and a 3% dividend yield and waiting to see if Cellebrex gets FDA OK. Downside is pretty limited.
Gavin GrahamOwned
biotechnologypharmaceutical
BUY
Big headline risk and he loves stock with headline risks. Trading at a 50% discount to what it's really worth.
Brian Acker, CAOwned
biotechnologypharmaceutical
BUY
All the drug stocks in the US have dropped, but this had the best performance of all of them. Their Cellebrex has not been pulled and this has created some negatives. 3.2% yield and if it turns out the FDA finds no problem with the drug, it will be a major factor. Selling for 11 X earnings. Good price.
Gavin GrahamOwned
biotechnologypharmaceutical
TOP PICK
The industry as a whole has been in a difficult time. A lot of the stuff has been discounted in the stock. Trading at a very cheap multiple. Lots of cash and a high dividend yield. Good long term hold 4/5 years.
Paul Harris, CFAOwned
biotechnologypharmaceutical
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20scale(-1,%201)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
